Reply to: “Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land”
Author(s):
Pan Zhao
Pan Zhao
Affiliations:
Corresponding author. Address: Clinical Trial Center, Liver Failure Therapy and Research Center, Beijing 302 Hospital, No.100 of West Fourth Ring Middle Road, Beijing 100039, China. Tel.: +86 10 66933464; fax: +86 10 66933020.
EASL LiverTree™. Zhao P. Nov 1, 2018; 234559
Pan Zhao
Pan Zhao
Contributions
Journal Abstract
References
This article does not have an abstract to display.
[1]. M.M. Jonas - Long-term growth outcomes in children treated for chronic hepatitis C
[2]. J. Chen - Factors influencing the curative effect in patients with HBeAg positive chronic hepatitis B treated with peg-interferon α-2a
[3]. S. Zhu - Reply to: “Immunotolerant children with chronic hepatitis B – To treat or not – The dilemma continues”
[4]. S. Zhu - Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: a pilot open-label randomized study

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies